Resumen:
Introducción. Trypanosoma cruzi, agente causal de la enfermedad de Chagas, exhibe una sustancial heterogeneidad fenotípica y genotípica que puede influir en las variaciones epidemiológicas y clínicas de la enfermedad, así como en la sensibilidad a los fármacos utilizados en el tratamient...
Cascabulho, Cynthia M;
Meuser-Batista, Marcelo;
Moura, Kelly Cristina G de;
Pinto, Maria do Carmo;
Duque, Thabata Lopes Alberto;
Demarque, Kelly C;
Guimarães, Ana Carolina Ramos;
Manso, Pedro Paulo de Abreu;
Pelajo-Machado, Marcelo;
Oliveira, Gabriel M;
Castro, Solange L De;
Menna-Barreto, Rubem FS.
BACKGROUND Chagas disease, which is caused by the protozoan Trypanosoma cruzi, is endemic to Latin America and mainly affects low-income populations. Chemotherapy is based on two nitrocompounds, but their reduced efficacy encourages the continuous search for alternative drugs. Our group has characterise...
Enfermedad Aguda,
Antiinflamatorios,
Enfermedad de Chagas/tratamiento farmacológico,
Modelos Animales de Enfermedad,
Electrocardiografía,
Naftoquinonas/química,
Naftoquinonas/uso terapéutico,
Nitroimidazoles/química,
Nitroimidazoles/uso terapéutico,
Parasitemia/tratamiento farmacológico,
Factores de Tiempo,
Tripanocidas/química,
Tripanocidas/uso terapéutico
Abstract INTRODUCTION: Benznidazole is used for treating Chagas disease (CD). This cross-sectional study aimed to characterize the adverse drug reactions (ADRs) of benznidazole at a public hospital in Brazil's Federal District. METHODS: Medical records were analyzed and ADRs were categorized by type,...
Brasil/epidemiología,
Enfermedad de Chagas/tratamiento farmacológico,
Estudios Transversales,
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología,
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos,
Pruebas de Hemaglutinación,
Hospitales Públicos,
Incidencia,
Persona de Mediana Edad,
Nitroimidazoles/efectos adversos,
Nitroimidazoles/uso terapéutico,
Índice de Severidad de la Enfermedad,
Factores Socioeconómicos,
Tripanocidas/efectos adversos,
Tripanocidas/uso terapéutico
Echeverría, Luis Eduardo;
González, Clara Isabel;
Hernandez, Julio Cesar Mantilla;
Díaz, Martha Lucia;
Eduardo Nieto, Javier;
López-Romero, Luis Alberto;
Rivera, Julián David;
Suárez, Edwin Uriel;
Ochoa, Sergio Alejandro Gómez;
Rojas, Lyda Z;
Morillo, Carlos A.
Abstract INTRODUCTION: Benznidazole (BZL) and Nifurtimox (NFX) are the pharmacological treatment for acute phase Chagas Disease (CD); however, therapy resistance and residual mortality development remain important unresolved issues. Posaconazole (POS) has shown a trypanocidal effect in vivo and in vitr...
Enfermedad Aguda,
Enfermedad de Chagas/tratamiento farmacológico,
ADN Protozoario,
Modelos Animales de Enfermedad,
Progresión de la Enfermedad,
Quimioterapia Combinada,
Nitroimidazoles/administración & dosificación,
Carga de Parásitos,
Parasitemia/tratamiento farmacológico,
Ratas Wistar,
Triazoles/administración & dosificación,
Tripanocidas/administración & dosificación
Ortiz, Jessica Vanina;
Pereira, Bruna Valessa Moutinho;
Couceiro, Katia do Nascimento;
Silva, Monica Regina Hosannah da Silva e;
Doria, Susan Smith;
Silva, Paula Rita Leite da;
Lira, Edson da Fonseca de;
Guerra, Maria das Graças Vale Barbosa;
Guerra, Jorge Augusto de Oliveira;
Ferreira, João Marcos Bemfica Barbosa.
Abstract Background: In the past two decades, a new epidemiological profile of Chagas' disease (CD) has been registered in the Brazilian Amazon where oral transmission has been indicated as responsible for the increase of acute cases. In the Amazonas state, five outbreaks of acute CD have been registere...
Brasil/epidemiología,
Cardiomiopatía Chagásica/diagnóstico por imagen,
Cardiomiopatía Chagásica/parasitología,
Enfermedad de Chagas/complicaciones,
Enfermedad de Chagas/tratamiento farmacológico,
Enfermedad de Chagas/epidemiología,
Ecocardiografía,
Electrocardiografía,
Estudios de Seguimiento,
Nitroimidazoles/uso terapéutico,
Tripanocidas/uso terapéutico,
Trypanosoma cruzi/aislamiento & purificación
Abstract Heart transplantation is an effective treatment for Chagas disease patients with severe cardiomyopathy. However, Trypanosoma cruzi reactivation is of great concern. The T. cruzi parasite is classified into six discrete typing units (DTUs identified as TcI-TcVI). It is unknown whether there is an...
Cardiomiopatía Chagásica/tratamiento farmacológico,
Cardiomiopatía Chagásica/cirugía,
ADN Protozoario,
Variación Genética,
Genotipo,
Trasplante de Corazón/efectos adversos,
Inmunosupresores/uso terapéutico,
Persona de Mediana Edad,
Nitroimidazoles/uso terapéutico,
Reacción en Cadena de la Polimerasa,
Tripanocidas/uso terapéutico
Von Trompowsky, Ana Claudia Manoel;
Conde, Taline Ramos;
Lemos, Renata Calil;
Quaresma, Bruna Maria CS;
Pitombeira, Marcelly Cristina SR;
de Carvalho, Alcione Silva;
Boechat, Núbia;
Salomão, Kelly;
de Castro, Solange Lisboa;
Zamith, Helena Pereira da Silva.
BACKGROUND Only benznidazole (Bnz) (1) and nifurtimox (Nfx) (2) are licensed for the treatment of Chagas disease although their safety and efficacy profile are far from ideal. Farmanguinhos from Fiocruz has developed seven nitroimidazole compounds (4-10) analogs of megazol (3). OBJECTIVES To evaluate ...
Abstract Chagas disease is a chronic parasitological disease, which could cause cardiac manifestations in approximately one-third of affected individuals. Benznidazole and nifurtimox are used to treat this parasitological infection caused by Trypanosoma cruzi. Conventionally, the criterion for cure is co...
Abstract Chagas disease is a protozoan infection that was identified over a century ago. No drugs are available to treat the indeterminate and determinate chronic phases of the disease. Success of a drug design is dependent on correct biological evaluation. Concerning new drug designs for Chagas disease,...
